JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, the combination treatment displays synergism, suggesting that simultaneously targeting BCR-ABL and JAK2 activities in CML stem/progenitor cells is indeed more effective than using single agents.